Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.
about
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesEmerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in OncologyOther paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer TreatmentModified Gompertz equation for electrotherapy murine tumor growth kinetics: predictions and new hypotheses.Objective assessment of tumour response to therapy based on tumour growth kinetics.Association of smoking with tumor size at diagnosis in non-small cell lung cancerTherapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With EribulinThe current and emerging role of immunotherapy in prostate cancerFrom clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancerDemystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.Simplifying the complexity of resistance heterogeneity in metastasisThe VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.Evaluation of tumor size response metrics to predict survival in oncology clinical trials.Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.Integrating Immunotherapies in Prostate Cancer.Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.Comparison of ACINUS, caspase-3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysisNeutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.The effect of intrinsic and acquired resistances on chemotherapy effectiveness.The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
P2860
Q27008070-5DF85A84-A116-485F-9D7D-F6D6F922BE0BQ30438965-2ADABEDC-4682-40AA-B1C0-843B6BDE5486Q33510328-7F4FD773-0FE6-4D3F-9DF4-A4386C673E1CQ33567889-5694584A-41F8-43AB-A911-1F571A3BF9C2Q33718182-348DB8EB-1FC1-4EFB-B7E8-A06C01E88B5DQ33732113-47E95719-4196-41A7-9C05-1CAEAABA7FFAQ35287641-CB71AF55-1465-4FBA-98F1-D9E8087B17B2Q35391331-5AEBAFF2-34D5-4EF2-8F6C-D5160E07D941Q35584269-01141752-162B-497C-BD33-CD2068068ADDQ35837560-B02DC6DC-307A-4DAB-AC98-9185844C7B6DQ35894702-70F5669F-4AC5-44FC-9B71-B40DD9086C1DQ35979551-6021809D-1F45-4FD2-934D-0D421F40EBBBQ36249922-7580AEFD-F5F0-40FA-B338-3D6D43F8CDD5Q36293995-7B0090E6-53D3-45D0-B401-02ED41ACB2C9Q36567448-7AF10181-10D6-4588-A95A-AEA6F603B99BQ36708792-9FBD4918-1534-43E7-B79A-CE7F13177B0CQ37017101-94795F3E-1098-49BA-88D5-6F723FD3CE15Q37224581-65CD667C-38FB-48CD-ABA7-190BB3302EADQ37655188-3D30FFD8-6A53-4231-B805-FE5ED70F472CQ37681171-CC9B4FAD-1524-49B4-9850-4574F31DC7F9Q38178093-88570F25-8F24-4402-A698-78AEF112B47DQ38351470-33A3F4F8-AF7F-4B9F-ABDC-9431BC81966EQ38567067-4A9E4588-04E0-49BC-818F-F487B767E63FQ39791929-397AC8B2-53F2-4CC8-9AA7-FEFD894C24E9Q41967831-2BC4CA35-E41F-470B-9B67-2A9BD8D0231FQ42370649-B95BD178-0A18-4257-B784-B1505DF77928Q44244571-6A957027-AB39-4030-901F-07BDD52B3EE2Q50951071-FC84DA87-77FB-4E3B-B93A-BFBE93815220Q54640859-CD8E00A9-FDF1-448D-8655-A1923DABDE99
P2860
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Tumor growth rates derived fro ...... uation of clinical trial data.
@ast
Tumor growth rates derived fro ...... uation of clinical trial data.
@en
type
label
Tumor growth rates derived fro ...... uation of clinical trial data.
@ast
Tumor growth rates derived fro ...... uation of clinical trial data.
@en
prefLabel
Tumor growth rates derived fro ...... uation of clinical trial data.
@ast
Tumor growth rates derived fro ...... uation of clinical trial data.
@en
P2093
P2860
P1433
P1476
Tumor growth rates derived fro ...... uation of clinical trial data.
@en
P2093
Doug Price
Moshe B Hoshen
Susan E Bates
Wilfred D Stein
William Dahut
William Doug Figg
P2860
P304
P356
10.1634/THEONCOLOGIST.2008-0075
P577
2008-10-06T00:00:00Z